Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Atea Pharmaceuticals Inc (AVIR) Insider Trading Activity
Healthcare • Biotechnology • 75 employees
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Total Value
-$1,561,101.44
Total Shares
-30,462
Average Trade Value
-$65,045.89
Most Active Insider
Berger Franklin M
Total Activity: $1,104,973
Largest Single Transaction
$1,023,475
by Berger Franklin M on Dec 10, 2024
30-Day Activity
20 Transactions
Volume: 387,113 shares
Value: $303,472
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Evp, Chief Accounting Officer
|
Jan 31, 2025 | 12,062 | $36,910 | 50,128 (-24.1%) | Payment of Exercise Price | |
|
President, Ceo, and Chairman
|
Jan 31, 2025 | 99,517 | $10,000 | 389,541 (+25.5%) | Grant | |
|
Evp, Chief Accounting Officer
|
Jan 31, 2025 | 33,333 | $10,000 | 54,190 (+61.5%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Jan 31, 2025 | 33,333 | $10,000 | 54,848 (+60.8%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Jan 31, 2025 | 8,750 | $10,000 | 63,598 (+13.8%) | Grant | |
|
Evp, Chief Accounting Officer
|
Jan 31, 2025 | 8,000 | $10,000 | 62,190 (+12.9%) | Grant | |
|
Chief Commercial Officer
|
Jan 31, 2025 | 11,517 | $35,242 | 52,081 (-22.1%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Jan 31, 2025 | 9,750 | $10,000 | 76,947 (+12.7%) | Grant | |
|
Chief Development Officer
|
Jan 31, 2025 | 14,134 | $43,250 | 81,388 (-17.4%) | Payment of Exercise Price | |
|
Chief Development Officer
|
Jan 31, 2025 | 11,250 | $10,000 | 95,522 (+11.8%) | Grant | |
|
Chief Development Officer
|
Jan 31, 2025 | 46,800 | $0 | 84,272 (+55.5%) | Exercise/Conversion | |
|
See Remarks
|
Jan 31, 2025 | 10,500 | $10,000 | 733,409 (+1.4%) | Grant | |
|
See Remarks
|
Jan 31, 2025 | 44,367 | $0 | 722,909 (+6.1%) | Exercise/Conversion | |
|
President, Ceo, and Chairman
|
Jan 31, 2025 | 88,601 | $271,119 | 300,940 (-29.4%) | Payment of Exercise Price | |
|
See Remarks
|
Jan 31, 2025 | 16,102 | $49,272 | 717,307 (-2.2%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Jan 31, 2025 | 41,533 | $10,000 | 67,197 (+61.8%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Jan 31, 2025 | 16,071 | $49,177 | 60,876 (-26.4%) | Payment of Exercise Price | |
|
President, Ceo, and Chairman
|
Jan 31, 2025 | 173,467 | $10,000 | 290,024 (+59.8%) | Exercise/Conversion | |
| Jan 16, 2025 | 10,000 | $33,614 | 476,897 (+2.1%) | Purchase | ||
| Jan 15, 2025 | 15,000 | $47,885 | 466,897 (+3.2%) | Purchase | ||
| Dec 10, 2024 | 359,606 | $1,023,475 | 451,897 (-79.6%) | Sale | ||
|
President, Ceo, and Chairman
|
Sep 19, 2024 | 1,841 | $7,368 | 5,866,025 (-0.0%) | Sale | |
|
President, Ceo, and Chairman
|
Sep 18, 2024 | 22,187 | $89,469 | 5,867,866 (-0.4%) | Sale | |
|
President, Ceo, and Chairman
|
Sep 17, 2024 | 33,941 | $137,319 | 5,890,053 (-0.6%) | Sale |